As of 2025-04-21, the EV/EBITDA ratio of Fulgent Genetics Inc (FLGT) is -10.32. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLGT's latest enterprise value is 499.86 mil USD. FLGT's TTM EBITDA according to its financial statements is -48.44 mil USD. Dividing these 2 quantities gives us the above FLGT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.2x - 15.9x | 13.0x |
| Forward P/E multiples | 9.0x - 12.9x | 11.2x |
| Fair Price | (12.77) - (18.64) | (17.24) |
| Upside | -171.5% - -204.3% | -196.5% |
| Date | EV/EBITDA |
| 2025-04-15 | -10.97 |
| 2025-04-14 | -11.01 |
| 2025-04-11 | -11.05 |
| 2025-04-10 | -9.98 |
| 2025-04-09 | -10.19 |
| 2025-04-08 | -9.80 |
| 2025-04-07 | -9.83 |
| 2025-04-04 | -9.68 |
| 2025-04-03 | -9.77 |
| 2025-04-02 | -10.17 |
| 2025-04-01 | -9.97 |
| 2025-03-31 | -9.71 |
| 2025-03-28 | -9.80 |
| 2025-03-27 | -9.68 |
| 2025-03-26 | -9.71 |
| 2025-03-25 | -9.80 |
| 2025-03-24 | -9.75 |
| 2025-03-21 | -9.83 |
| 2025-03-20 | -9.70 |
| 2025-03-19 | -9.69 |
| 2025-03-18 | -9.85 |
| 2025-03-17 | -10.01 |
| 2025-03-14 | -9.92 |
| 2025-03-13 | -9.76 |
| 2025-03-12 | -10.08 |
| 2025-03-11 | -10.06 |
| 2025-03-10 | -9.69 |
| 2025-03-07 | -10.78 |
| 2025-03-06 | -10.34 |
| 2025-03-05 | -9.55 |
| 2025-03-04 | -8.83 |
| 2025-03-03 | -8.68 |
| 2025-02-28 | -8.78 |
| 2025-02-27 | -8.94 |
| 2025-02-26 | -9.29 |
| 2025-02-25 | -9.32 |
| 2025-02-24 | -9.61 |
| 2025-02-21 | -9.43 |
| 2025-02-20 | -9.54 |
| 2025-02-19 | -9.99 |
| 2025-02-18 | -9.69 |
| 2025-02-14 | -9.71 |
| 2025-02-13 | -9.68 |
| 2025-02-12 | -9.27 |
| 2025-02-11 | -9.31 |
| 2025-02-10 | -9.24 |
| 2025-02-07 | -9.22 |
| 2025-02-06 | -9.50 |
| 2025-02-05 | -9.67 |
| 2025-02-04 | -9.38 |